These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2142 related articles for article (PubMed ID: 27156933)

  • 1. Gastric cancer.
    Van Cutsem E; Sagaert X; Topal B; Haustermans K; Prenen H
    Lancet; 2016 Nov; 388(10060):2654-2664. PubMed ID: 27156933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab: first global approval.
    Poole RM; Vaidya A
    Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
    Tehfe M; Tabchi S; Laterza MM; De Vita F
    Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
    Lévêque I; Spitzer E
    Bull Cancer; 2024 Feb; 111(2):130-132. PubMed ID: 38071114
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
    Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U; Shah MA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
    [No Abstract]   [Full Text] [Related]  

  • 12. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
    Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric Carcinoma at the Era of Targeted Therapies.
    Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
    Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
    Hofheinz RD; Lorenzen S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab: A Review in Advanced Gastric Cancer.
    Greig SL; Keating GM
    BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
    Hicks DG; Whitney-Miller C
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the therapeutic landscape of oesophago-gastric cancers.
    Fokter Dovnik N; Smyth EC
    Curr Opin Oncol; 2021 Jul; 33(4):362-367. PubMed ID: 33720069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
    Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
    Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
    Maron SB; Catenacci DVT
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 directed therapy for gastric/esophageal cancers.
    Won E; Janjigian YJ; Ilson DH
    Curr Treat Options Oncol; 2014 Sep; 15(3):395-404. PubMed ID: 24811128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 108.